Research

Unlike commercially insured individuals who have no cost sharing for recommended vaccinations, in 2021, Medicare beneficiaries receiving vaccines covered under Medicare Part D paid $234 million out of pocket (OOP), with a mean OOP cost of $76.94 for shingles vaccines.

CED has the potential to improve access to technologies, promote innovation, and drive evidence generation. However, CMS, manufacturers, researchers, policy makers, patients, and others must first work together.

Research findings highlight the need for improved recruitment strategies to include more diverse participants in Alzheimer’s clinical trials.

Low- net health benefit (NHB) targeted cancer drugs (TCDs) were prescribed less frequently than medium- and high-net NHB TCDs. Total spending on oral TCDs was high and positively associated with NHB.

Lower rates of behavioral and psychological symptoms of dementia diagnoses in non-white compared to white populations may indicate underdiagnosis in clinical settings of treatable conditions.

The predictive algorithm with features generated by machine learning achieved significantly improved prediction of pressure injury risk.

DLEUs and VLUs treated with vCPM and vLPM allografts are associated with lowered 1-year mortality, wound recurrence, and AOs in DLEUs and VLUs compared with standard care. Decision makers weighing coverage of placental allografts should consider these added short- and long-term clinical benefits relative to costly management and high mortality of Medicare’s most frequent wounds.

Research findings suggest that policies limiting hospitals’ promotion of MPPs may need to be coupled with efforts to stabilize hospital finances, as hospitals may be using MPP promotion when they lack the resources to offer long-term interest-free financing.

Abstract Rising prices are a major cause of increased health care spending and health insurance premiums in the US. Hospital prices, specifically—for both inpatient and outpatient care—are the largest driver of rising health care spending in the commercial insurance market. As a result, policy makers and employers are increasingly interested in understanding the determinants of […]

Part D plans became significantly more restrictive over time, rising from an average of 31.9 percent of compounds restricted in 2011 to 44.4 percent restricted in 2020.